Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorPrager, Gerald W
dc.contributor.authorWestphalen, C Benedikt
dc.contributor.authorD'Esquermes, Nathalie
dc.contributor.authorFerreras, Anabel
dc.contributor.authorMacarulla Mercadé, Teresa
dc.contributor.authorTaieb, Julien
dc.contributor.authorMelisi, Davide
dc.date.accessioned2021-10-22T05:44:42Z
dc.date.available2021-10-22T05:44:42Z
dc.date.issued2020-01-20
dc.identifier.citationTaieb J, Prager GW, Melisi D, Westphalen CB, D’Esquermes N, Ferreras A, et al. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. ESMO Open. 2020 Jan 20;5:e000587.
dc.identifier.issn2059-7029
dc.identifier.urihttps://hdl.handle.net/11351/6435
dc.descriptionEuropa occidental; Gemcitabina; Càncer de pàncrees
dc.description.sponsorshipThe study was funded by Shire (Zug, Switzerland). Medical writing assistance was initially funded by Shire and subsequently by Servier Global Medical Affairs (Suresnes, France). Although employees of the sponsor were involved in the design, collection, analysis, interpretation, fact checking of information, and coordination and collation of comments, the content of this manuscript, the interpretation of the data and the decision to submit the manuscript for publication in ESMO Open were made by the authors independently.
dc.language.isoeng
dc.publisherBMJ
dc.relation.ispartofseriesESMO Open;5
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectPàncrees - Càncer - Quimioteràpia
dc.subjectAdenocarcinoma - Quimioteràpia
dc.subject.meshPancreatic Neoplasms
dc.subject.meshAdenocarcinoma
dc.subject.mesh/drug therapy
dc.titleFirst-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1136/esmoopen-2019-000587
dc.subject.decsneoplasias pancreáticas
dc.subject.decsadenocarcinoma
dc.subject.decs/farmacoterapia
dc.relation.publishversionhttps://doi.org/10.1136/esmoopen-2019-000587
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Taieb J] Hôpital Européen Georges Pompidou, AP-HP, Paris, France. Sorbonne Paris Cité, Université Paris Descartes, Paris, France. [Prager GW] Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria. [Melisi D] Digestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli Studi di Verona, Verona, Veneto, Italy. [Westphalen CB] Department of Medicine III and Comprehensive Cancer Center Munich, University Hospital LMU Munich, Munich, Germany. [D'Esquermes N, Ferreras A] Genactis SAS, Mougins, France. [Macarulla T] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid31958291
dc.identifier.wos000527764500006
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail
Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple